ストックスクリーナーアプリを入手
2.31
2.13%
-0.04
前日終値:
$2.35
開ける：
$2.32
24時間の取引高:
27,677
Relative Volume:
0.08
時価総額：
$101.45M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.12%
1か月 パフォーマンス:
-20.69%
6か月 パフォーマンス:
-56.11%
1年 パフォーマンス:
-90.10%
1日の値動き範囲:
$2.29
$2.354
1週間の範囲:
$2.20
$2.47
52週間の値動き範囲:
$2.20
$25.84
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
名前
Kyverna Therapeutics Inc
セクター
電話
(510) 626-8331
住所
5980 HORTON STREET, EMERYVILLE
KYTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.31 | 101.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.67 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
656.71 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
289.23 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
610.34 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
255.17 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-03 | 開始されました | H.C. Wainwright | Neutral |
| 2024-03-04 | 開始されました | JP Morgan | Overweight |
| 2024-03-04 | 開始されました | Leerink Partners | Outperform |
| 2024-03-04 | 開始されました | Morgan Stanley | Overweight |
| 2024-03-04 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Kyverna Therapeutics Inc (KYTX) 最新ニュース
Notice to Long-Term Shareholders of Akero Therapeutics, - GlobeNewswire
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is I - TradingView
Why Kyverna Therapeutics Stock Is Sinking - MSN
Investors Who Lost Money on Kyverna Therapeutics, Inc. (KYTX) Should Contact Levi & Korsinsky About Pending Class ActionKYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More Information – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics stock hits 52-week low at $2.24 - Investing.com
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
Kyverna Therapeutics stock hits 52-week low at $2.24 By Investing.com - Investing.com South Africa
Notice to Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Clai - Morningstar
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lupus Nephritis Clinical and Non-Clinical Studies, Key - openPR
GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna - Business Wire
Notice to Long-Term Shareholders of Archer-Daniels-Midland - GlobeNewswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: - GlobeNewswire
KYTX stock touches 52-week low at $2.49 amid market challenges - Investing.com Australia
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Rhumbline Advisers Purchases 6,153 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics stock hits 52-week low at $2.64 By Investing.com - Investing.com Australia
Kyverna Therapeutics to Present at the Leerink Partners Global B - GuruFocus.com
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PR Newswire
Kyverna Therapeutics stock hits 52-week low at $2.64 - Investing.com
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc. (KYTX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Kyverna Therapeutics To Present At The Leerink Partners Global Biopharma Conference - MENAFN.COM
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Head-To-Head Survey: Pluri (NASDAQ:PLUR) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
3 US Penny Stocks With Market Caps Under $200M - Yahoo Finance
KYTX stock touches 52-week low at $2.78 amid sharp annual decline - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $25.71 Consensus Price Target from Analysts - Defense World
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Leerink Partnrs Issues Optimistic Estimate for KYTX Earnings - MarketBeat
KYTX stock touches 52-week low at $2.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Equities Analysts Set Expectations for KYTX FY2025 Earnings - Defense World
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock - MSN
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Kilgore News Herald
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com
2025-02-07 | FINAL REMINDER KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Kyverna Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit | NDAQ:KYTX | Press Release - Stockhouse Publishing
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - TradingView
Kyverna Therapeutics Inc (KYTX) 財務データ
Kyverna Therapeutics Inc (KYTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Kyverna Therapeutics Inc (KYTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
0.00%
0.50%
大文字化:
|
ボリューム (24 時間):